ANI Pharmaceuticals (NASDAQ:ANIP) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.95 by $0.07, Briefing.com reports. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The company had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same quarter in the prior year, the business posted $1.06 EPS. ANI Pharmaceuticals’s quarterly revenue was up 18.5% on a year-over-year basis. ANI Pharmaceuticals updated its FY24 guidance to $4.38-4.82 EPS and its FY 2024 guidance to 4.380-4.820 EPS.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $63.29 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.95 and a quick ratio of 3.12. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The firm has a fifty day moving average price of $63.12 and a two-hundred day moving average price of $63.29. The company has a market cap of $1.33 billion, a PE ratio of 39.56 and a beta of 0.75.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $64.41, for a total value of $1,288,200.00. Following the completion of the sale, the senior vice president now directly owns 213,226 shares of the company’s stock, valued at approximately $13,733,886.66. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, SVP Ori Gutwerg sold 2,985 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $67.00, for a total transaction of $199,995.00. Following the completion of the transaction, the senior vice president now directly owns 77,227 shares of the company’s stock, valued at approximately $5,174,209. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $64.41, for a total transaction of $1,288,200.00. Following the transaction, the senior vice president now directly owns 213,226 shares of the company’s stock, valued at $13,733,886.66. The disclosure for this sale can be found here. Insiders sold a total of 148,202 shares of company stock valued at $9,387,374 in the last ninety days. Company insiders own 12.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Guggenheim reaffirmed a “buy” rating and set a $77.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. HC Wainwright upped their price objective on shares of ANI Pharmaceuticals from $87.00 to $94.00 and gave the stock a “buy” rating in a report on Wednesday, June 26th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $82.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.